Get informed when a big investor buys or sells
+ FollowUndervalued by 37.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $1.78 Billion |
|---|---|
| Enterprise Value | $2.28 Billion |
| Annual dividend | $0.46 |
| Dividend yield | 1.65% |
| Earnings per Share | $1.24 |
| Beta | 0.39 |
| Outstanding Shares | 73,295,000 |
| P/E Ratio | 19.36 |
|---|---|
| PEG | 1230.16 |
| Price to Sales | 1.02 |
| Price to Book Ratio | 3.3 |
| Enterprise Value to Revenue | 1.17 |
| Enterprise Value to EBIT | 7.87 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 1.07 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond ...